Skip to main content

Table 1 Drugs for MS patients targeting remyelination in clinical trials

From: Central nervous system regeneration: the roles of glial cells in the potential molecular mechanism underlying remyelination

Drug

Drug type

Details

Subtype

ClinicalTrails.gov identifier

GNbAc1

Monoclonal antibody

Assess the efficacy of HERV-W Env antagonist in MS

RRMS

NCT02782858

GSK239512

Histamine H, receptor antagonist

Evaluate whether it can remyelinate lesions in patients

RRMS

NCT01772199

Opicinumab (BIIB033)

Anti-lingo-1 monoclonal antibody

Efficacy, safety and dose tolerability for CNS remyelination

RRMS

NCT01864148

Domperidone

Dopamine D2 antagonist

Study myelin repair in patients with enhancing lesion by MRI

RRMS

NCT02493049

Clemastine Fumarate

Antihistaminic

Assessment of its tolerability as a remyelinating agent

RRMS

NCT02040298

Vaginal estriol

Estrogen

Evaluate the efficiency and remyelination role in female patients with urogenital symptoms

RRMS

NCT03774407

Liothyronine

Thyroid hormone

Safety and dose finding study of remyelination

RRMS, SPMS, PPMS

NCT02760056

Olesoxime

Cholesterol-like neuroprotectant

Measurement of remyelination by MRI

RRMS

NCT01808885

Natalizumab

Anti-integrin monoclonal antibody

Evaluate the remyelination capacity

RRMS

NCT00937677

Quetiapine fumarate

Atypical Antipsychotic

Safety and tolerability of this remyelinating agent in patients

RRMS, RPMS

NCT02087631

Alemtuzumab

Anti-CD52 monoclonal antibody

MRI measurement of remyelination

RRMS

NCT01395316

Adrenocorticotropic hormone (ACTH)

Hormone

Evaluate the effect of ACTH for treating demyelination in patients

RRMS, SPMS

NCT00854750

Bazedoxifene acetate

Selective estrogen receptor modulator

Test the efficacy of the drug as a remyelinating agent

RRMS

NCT04002934

  1. Data listed in the table are collected from ClinicalTrials.gov by searching the terms “remyelination” within the condition of “multiple sclerosis.” RRMS relapsing remitting multiple sclerosis, SPMS secondary progressive multiple sclerosis, PPMS primary progressive MS, CNS central nervous system, HERV human endogenous retrovirus, Env envelope protein, MRI magnetic resonance imaging